These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17947521)

  • 21. Studies on the role of neutralizing antibodies against envelope genes in resolving HCV pseudo-particles infection.
    Rafique S; Idrees M; Ali A; Iqbal M
    Mol Biol Rep; 2014 Jun; 41(6):3945-50. PubMed ID: 24566682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion.
    Haberstroh A; Schnober EK; Zeisel MB; Carolla P; Barth H; Blum HE; Cosset FL; Koutsoudakis G; Bartenschlager R; Union A; Depla E; Owsianka A; Patel AH; Schuster C; Stoll-Keller F; Doffoël M; Dreux M; Baumert TF
    Gastroenterology; 2008 Nov; 135(5):1719-1728.e1. PubMed ID: 18718838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus.
    Johansson DX; Voisset C; Tarr AW; Aung M; Ball JK; Dubuisson J; Persson MA
    Proc Natl Acad Sci U S A; 2007 Oct; 104(41):16269-74. PubMed ID: 17911260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Junctional and somatic hypermutation-induced CX
    Yi C; Xia J; He L; Ling Z; Wang X; Yan Y; Wang J; Zhao X; Fan W; Sun X; Zhang R; Ye S; Zhang R; Xu Y; Ma L; Zhang Y; Zhou H; Huang Z; Niu J; Long G; Lu J; Zhong J; Sun B
    Cell Mol Immunol; 2021 Mar; 18(3):675-685. PubMed ID: 32235917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.
    Swann RE; Cowton VM; Robinson MW; Cole SJ; Barclay ST; Mills PR; Thomson EC; McLauchlan J; Patel AH
    J Virol; 2016 May; 90(9):4530-4543. PubMed ID: 26912610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies.
    Stamataki Z; Coates S; Evans MJ; Wininger M; Crawford K; Dong C; Fong YL; Chien D; Abrignani S; Balfe P; Rice CM; McKeating JA; Houghton M
    Vaccine; 2007 Nov; 25(45):7773-84. PubMed ID: 17919789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2.
    Vasiliauskaite I; Owsianka A; England P; Khan AG; Cole S; Bankwitz D; Foung SKH; Pietschmann T; Marcotrigiano J; Rey FA; Patel AH; Krey T
    mBio; 2017 May; 8(3):. PubMed ID: 28512091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.
    Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.
    Dreux M; Pietschmann T; Granier C; Voisset C; Ricard-Blum S; Mangeot PE; Keck Z; Foung S; Vu-Dac N; Dubuisson J; Bartenschlager R; Lavillette D; Cosset FL
    J Biol Chem; 2006 Jul; 281(27):18285-95. PubMed ID: 16675450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.
    Colbert MD; Flyak AI; Ogega CO; Kinchen VJ; Massaccesi G; Hernandez M; Davidson E; Doranz BJ; Cox AL; Crowe JE; Bailey JR
    J Virol; 2019 Jul; 93(14):. PubMed ID: 31068427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Humoral immune system targets clonotypic antibody-associated hepatitis C virus.
    Naik AS; Palmer BA; Crosbie O; Kenny-Walsh E; Fanning LJ
    J Gen Virol; 2017 Feb; 98(2):179-189. PubMed ID: 28284234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody.
    Li Y; Pierce BG; Wang Q; Keck ZY; Fuerst TR; Foung SK; Mariuzza RA
    J Biol Chem; 2015 Apr; 290(16):10117-25. PubMed ID: 25737449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer.
    Guest JD; Wang R; Elkholy KH; Chagas A; Chao KL; Cleveland TE; Kim YC; Keck ZY; Marin A; Yunus AS; Mariuzza RA; Andrianov AK; Toth EA; Foung SKH; Pierce BG; Fuerst TR
    Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33431677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins.
    Kalemera MD; Capella-Pujol J; Chumbe A; Underwood A; Bull RA; Schinkel J; Sliepen K; Grove J
    J Gen Virol; 2021 Jan; 102(1):. PubMed ID: 33147126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp).
    Bailey JR; Urbanowicz RA; Ball JK; Law M; Foung SKH
    Methods Mol Biol; 2019; 1911():441-450. PubMed ID: 30593644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro selection of a neutralization-resistant hepatitis C virus escape mutant.
    Gal-Tanamy M; Keck ZY; Yi M; McKeating JA; Patel AH; Foung SK; Lemon SM
    Proc Natl Acad Sci U S A; 2008 Dec; 105(49):19450-5. PubMed ID: 19052239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference.
    Sautto G; Mancini N; Diotti RA; Solforosi L; Clementi M; Burioni R
    Antiviral Res; 2012 Oct; 96(1):82-9. PubMed ID: 22898087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies.
    Das S; Mullick R; Kumar A; Tandon H; Bose M; Gouthamchandra K; Chandra M; Ravishankar B; Khaja MN; Srinivasan N; Das S; Melkote Subbarao S; Karande AA
    J Gen Virol; 2017 May; 98(5):962-976. PubMed ID: 28221101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.
    Tarr AW; Urbanowicz RA; Hamed MR; Albecka A; McClure CP; Brown RJ; Irving WL; Dubuisson J; Ball JK
    J Virol; 2011 May; 85(9):4246-57. PubMed ID: 21325403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.